Terumo BCT
22
0
0
21
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
4.5%
1 terminated/withdrawn out of 22 trials
95.5%
+8.9% vs industry average
9%
2 trials in Phase 3/4
71%
15 of 21 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Trima Non-DEHP Leukoreduced Red Blood Cell In Vivo Recovery Study
Role: lead
Mirasol Evaluation of Reduction in Infections Trial
Role: collaborator
An In Vivo 24-Hour Recovery Study of Whole Blood by the Reveos System
Role: lead
Plasma Adsorption in Patients With Confirmed COVID-19
Role: collaborator
Maintenance Plasma Exchange for Neuromyelitis Optica
Role: collaborator
Intra Articular Injections With Platelet Rich Plasma in Patients With Juvenile Osteochondritis Dissecans of the Knee
Role: collaborator
In Vivo Recovery and Survival Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution
Role: lead
Pathogen Reduction Evaluation & Predictive Analytical Rating Score
Role: collaborator
Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion
Role: lead
Evaluation of Trima Version 7.0 Platelets in PAS
Role: lead
Evaluation of Trima Version 7.0 Platelets in 100% Plasma
Role: lead
In Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution
Role: lead
Trima Accel® System Post Count Algorithm Study
Role: lead
Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions
Role: lead
An Evaluation of the Spectra Optia CMNC Collection Procedure
Role: lead
Italian Platelet Technology Assessment Study
Role: collaborator
Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®
Role: collaborator
High Yield Intraoperative, Autologous Platelet Apheresis
Role: collaborator
Evaluation of the Spectra Optia PMN Cell Collection Procedure
Role: lead
Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients
Role: lead